Bristol-Myers Squibb

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 32,500 full-time employees.  The company is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).

Bristol Myers Squibb Co. terlibat dalam penemuan, pengembangan, lisensi, manufaktur, pemasaran, distribusi, dan penjualan produk biopharmaceutical. Perusahaan ini berkantor pusat di Princeton, New Jersey dan saat ini mempekerjakan 32.500 karyawan penuh waktu. Perusahaan ini terlibat dalam penemuan, pengembangan, dan penyampaian obat transformatif untuk pasien yang menghadapi penyakit serius di bidang: onkologi, hematologi, imunologi, kardiovaskular, neurologi, dan bidang lainnya. Portofolio pertumbuhannya mencakup Opdivo (nivolumab), Opdivo Qvantig (nivolumab dan hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab dan relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), dan Cobenfy (xanomeline dan trospium chloride). Produk pertumbuhan lainnya termasuk Augtyro, Onureg, Inrebic, Nulojix, dan Empliciti. Portofolio warisannya mencakup Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), dan Abraxane (partikel paclitaxel albumin-bound untuk suspensi injeksi).

Bristol-Myers Squibb Stock

About Bristol-Myers Squibb

Key Statistics

Insights